Recommendations for primary prevention of AF with
‘upstream’ therapy

Recommendations 

Evidencia
ACEIs and ARBs should be considered for prevention of newonset
AF in patients with heart failure and reduced ejection fraction.
IIa A
ACEIs and ARBs should be considered for prevention of new-onset
AF in patients with hypertension, particularly with left ventricular
hypertrophy.
IIa B
Statins should be considered for prevention of new-onset AF after
coronary artery bypass grafting, isolated or in combination with
valvular interventions
IIa B
Statins may be considered for prevention of new-onset AF in patients
with underlying heart disease, particularly heart failure.
 
IIb B
Upstream therapies with ACEIs, ARBs, and statins are not recommended
for primary prevention of AF in patients without cardiovascular disease.
 
III C
ACEI: angiotensin-converting enzyme inhibitor; AF:atrial fibrillation; ARB:
angiotensin receptor blocker.

Volver